Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.

Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D.

Mov Disord. 2009 May 15;24(7):979-83. doi: 10.1002/mds.22401.

PMID:
19230029
[PubMed - indexed for MEDLINE]
2.

A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.

Jankovic J, Hunter C.

Parkinsonism Relat Disord. 2002 Mar;8(4):271-6.

PMID:
12039422
[PubMed - indexed for MEDLINE]
3.

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.

Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.

Mov Disord. 2010 Nov 15;25(15):2542-9. doi: 10.1002/mds.23317.

PMID:
20669317
[PubMed - indexed for MEDLINE]
4.

Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.

Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.

Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:41-9.

PMID:
15496222
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W; Pramipexole ER Studies Group.

Neurology. 2011 Aug 23;77(8):767-74. doi: 10.1212/WNL.0b013e31822affdb. Epub 2011 Aug 10.

PMID:
21832216
[PubMed - indexed for MEDLINE]
6.
7.

Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.

Kieburtz K; Parkinson Study Group PramiBID Investigators.

Mov Disord. 2011 Jan;26(1):37-44. doi: 10.1002/mds.23396. Epub 2010 Oct 5.

PMID:
20925067
[PubMed - indexed for MEDLINE]
8.

A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations.

Clarke CE, Cooper JA, Holdich TA; TREMOR Study Group.

Clin Neuropharmacol. 2001 May-Jun;24(3):133-8.

PMID:
11391123
[PubMed - indexed for MEDLINE]
9.

Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease.

Goetz CG, Leurgans S, Raman R; Parkinson Study Group.

Mov Disord. 2002 Mar;17(2):283-8.

PMID:
11921113
[PubMed - indexed for MEDLINE]
10.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.

Lancet Neurol. 2011 May;10(5):415-23. doi: 10.1016/S1474-4422(11)70073-4. Epub 2011 Apr 7. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
21482191
[PubMed - indexed for MEDLINE]
11.

Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage.

Parkinson Study Group.

Clin Neuropharmacol. 2007 Mar-Apr;30(2):72-85.

PMID:
17414939
[PubMed - indexed for MEDLINE]
12.

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G.

Mov Disord. 2005 Aug;20(8):958-63.

PMID:
15800937
[PubMed - indexed for MEDLINE]
13.

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.

Shannon KM, Bennett JP Jr, Friedman JH.

Neurology. 1997 Sep;49(3):724-8. Erratum in: Neurology 1998 Mar;50(3):838.

PMID:
9305331
[PubMed - indexed for MEDLINE]
14.

Levodopa and the progression of Parkinson's disease.

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group.

N Engl J Med. 2004 Dec 9;351(24):2498-508.

PMID:
15590952
[PubMed - indexed for MEDLINE]
Free Article
15.
16.

The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.

Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.

Clin Ther. 2009 Jan;31(1):89-98. doi: 10.1016/j.clinthera.2009.01.012. Erratum in: Clin Ther. 2009 Mar;31(3):677.

PMID:
19243709
[PubMed - indexed for MEDLINE]
17.

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.

Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW.

Mov Disord. 2004 Aug;19(8):916-23.

PMID:
15300656
[PubMed - indexed for MEDLINE]
18.

Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study.

Schneider JS, Roeltgen DP, Mancall EL, Chapas-Crilly J, Rothblat DS, Tatarian GT.

Neurology. 1998 Jun;50(6):1630-6.

PMID:
9633704
[PubMed - indexed for MEDLINE]
19.

The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.

Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P; Parkinson-Control Study Group.

Mov Disord. 2006 Apr;21(4):500-9.

PMID:
16267842
[PubMed - indexed for MEDLINE]
20.

Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.

Oertel W, Poewe W, Wolters E, De Deyn PP, Emre M, Kirsch C, Hsu C, Tekin S, Lane R.

Drug Saf. 2008;31(1):79-94.

PMID:
18095748
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk